Please use this identifier to cite or link to this item:
Title: Clinical trials and graft patency data in coronary artery surgery--a 30-year perspective.
Austin Authors: Buxton, Brian F ;Fuller, John A
Affiliation: Department of Cardiac Surgery, Austin Hospital, Melbourne, Victoria, Australia
Issue Date: 2004
Publication information: Heart, Lung & Circulation; 13 Suppl 3(): S7-S12
Abstract: The treatment of coronary artery disease, initially by medical and surgical and subsequently using percutaneous interventions, has evolved rapidly over the last 50 years. Randomized controlled clinical trials and observational studies of large cohorts have been instrumental in the evolution of the current practice of coronary artery revascularisation. This paper traces some of the historic trials of medical versus surgical therapy, surgical versus percutaneous intervention and graft patency studies. Medical therapy and percutaneous intervention are now the primary therapeutic modalities. However, there was an early recurrence rate with percutaneous intervention which has decreased with the use of drug-eluting stents. Coronary artery bypass surgery remains a major option for treating advanced coronary artery disease. Furthermore, it remains the treatment of first choice in most patients with left main coronary artery disease and those with extensive three-vessel proximal coronary artery disease, especially when associated with poor left ventricular function. The choice of a coronary artery bypass conduit is of major importance in developing a single long-term strategy for the surgical treatment of coronary artery disease. Bilateral internal thoracic artery grafting is now accepted as the treatment of choice, although not universally practiced. The role of other arterial conduits is being defined.
Gov't Doc #: 16352242
DOI: 10.1016/j.hlc.2004.09.014
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.